Caribou Biosciences, Inc. (CRBU) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Caribou Biosciences, Inc. (CRBU) closed at USD 0.46 on 2026-10-14, a change of -81.4 % over the past year, with a market capitalization of USD 49.82M.

Caribou Biosciences, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Caribou Biosciences, Inc. key figures

Previous close

USD 0.46 (2026-10-14)

1-year change

-81.4 %

Market cap

USD 49.82M

Enterprise value

USD -35.84M

P/E ratio (trailing)

-0.46

P/E ratio (forward)

-0.52

EPS (trailing)

-1.01

EPS (forward)

-0.90

PEG ratio

n/a

Price to book

0.50

Revenue growth

-43.8 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

11.05

Employees

97

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Caribou Biosciences, Inc.

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Caribou Biosciences, Inc. and compare it with other stocks.